Titus Thorne

Last Updated March 12, 2023

Titus Thorne

 March 12, 2023

Curious about MK-677 in the UK?

If so, then you’ve come to the right place.

Below, our team of researchers details everything you MUST know about MK-677, including…

  • What is MK-677?
  • Is MK-677 legal in the UK?
  • Where to buy MK-677
  • MK-677 benefits
  • MK-677 side effects
  • MK-677 dosage

For citizens and residents of the UK, this is your definitive guide to MK-677. 

Buy MK-677 from the #1 online Peptides vendor in the world...

Disclaimer: Peptides.org contains information about products that are intended for laboratory and research use only, unless otherwise explicitly stated. This information, including any referenced scientific or clinical research, is made available for educational purposes only. Peptides.org makes every effort to ensure that any information it shares complies with national and international standards for clinical trial information and is committed to the timely disclosure of the design and results of all interventional clinical studies for innovative treatments publicly available or that may be made available. However, research is not considered conclusive. Peptides.org makes no claims that any products referenced can cure, treat or prevent any conditions, including any conditions referenced on its website or in print materials.

What is MK-677?

MK-677, also known as ibutamoren, is a synthetic nonpeptide growth hormone secretagogue (GHS) and ghrelin agonist, noted for its oral bioavailability and targeted stimulation of the GH/IGF-1 axis. It has primarily been studied as a potential treatment for growth hormone deficiency (GHD) in both children and adults. However, ongoing analysis indicates numerous further benefits, such as improved bone health, physical composition, and sleep quality in diverse populations [1, 2, 3].

First synthesized in 1995, MK-677 is functionally comparable to growth hormone-releasing peptide-6 (GHRP-6), an early synthetic GHS peptide. However, MK-677 is a peptide mimetic that was developed to exhibit greater stability than many peptide-based structures, granting it increased oral bioavailability and half-life in relation to GHRPs. MK-677 is currently designated as an orphan drug in the UK as a prospective treatment for growth hormone deficiency [2, 3, 4, 5, 6].

Therapeutic Potentials

Growth hormone secretagogues exhibit many therapeutic benefits in their stimulation of endogenous human growth hormone release within the pituitary gland. GH oversees healthy physical development from infancy onwards and is key to maintaining proper bone density, cardiovascular health, and physical composition in adulthood. Levels of GH are subject to natural decline with age, eliciting undesirable symptoms such as fatigue, weight gain, and sexual dysfunction [7].

When GH levels are pathologically low, a patient may be diagnosed with growth hormone deficiency (GHD). This condition can be acquired or congenital and can cause pediatric growth impairment, weakened muscles and bones, and metabolic disturbances. MK-677 is currently in clinical trials as an effective treatment for GHD, shown to elevate endogenous GH levels via stimulation of the GHS-R1a receptor, eliciting pulsatile release [2, 7].

In its targeted GH release and selective stimulation of the ghrelin receptor, MK-677 is also evidenced to promote bone and muscle growth in subjects that have not been diagnosed with GHD. Further areas of therapeutic potential beyond the scope of GHD treatment include improved sleep quality and body composition, as well as the treatment of neurodegenerative and cardiovascular diseases. Along with other growth hormone secretagogues, it is also of interest for anti-aging and healing benefits [2, 8].

While many popular peptidyl GH secretagogues such as GHRP-2, GHRP-6, and ipamorelin, exhibit optimal bioavailability via subcutaneous injection, MK-677 is uniquely suited to oral administration [9].

Buy MK-677 UK

Is MK-677 Legal in the UK?

MK-677 is classified as an uncontrolled and unprescribed substance in the United Kingdom. As such, it is not currently approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for sale as a medicinal product. However, it is fully legal for purchase and handling in research contexts, much like many experimental therapeutics in the United States under the restrictions of the Food and Drug Administration (FDA) [10, 11, 12].

Although legal for research purposes, MK-677 and other GH secretagogues have been banned by the Word Doping Association as performance-enhancing drugs due to their anabolic effects. Researchers should be advised that MK-677 is often misrepresented as a SARM, a class of androgenic compounds that closely mimics the effects of anabolic steroids. While increased GH levels are associated with androgenic effects, MK-677 is not a SARM nor an anabolic-androgenic steroid [13, 14].

Regulatory Landscape

Lacking regulatory approval, MK-677 and similar substances are often illegally manufactured and sold in an illicit market that is rife with unauthorized vendors and low-quality products. Multiple studies have shown that such clandestine products tend to be mislabeled and contain dangerous contaminants, presenting significant public health concerns in the UK and beyond [15, 16].

The lack of market approval and regulation in the production of novel peptide and nonpeptide therapeutics can be attributable in part to the relative lack of safety data on their long-term use in human subjects. In turn, the paucity of quality control measures in their production can hinder approval for clinical trials and sale as medical products. Despite these challenges, the arena of biosynthetic therapeutics has seen recent growth that is predicted to continue, prompting the European Medicines Agency (EMA) to issue guidelines for stronger quality assurance measures within the rapidly evolving field [17, 18, 19, 20, 21].

Purchase from a Credible Source

The good news is that UK researchers can legally acquire MK-677 for analysis. To ensure the purchase of high-quality and safe compounds from a legal vendor, experts advise patronizing only sources that meet the following standards of legitimacy [15, 16, 22, 23]:

  1. The retailer should state that all products are strictly for research uses.
  2. The marketing claims must not include direct medical guarantees regarding the administration of the product.
  3. Valid certificates of analysis from a third-party laboratory should be provided for all items to verify the chemical identity and purity.

With these measures in mind, researchers in the UK are encouraged to legally incorporate MK-677 into their studies.

Where to Buy MK-677 Online? | UK Edition

To get the most out of your research, it is critical to find a trusted source for all of your supplies. This is especially true when sourcing MK-677 and other therapeutic compounds.

We at Peptides.org appreciate this and have thoroughly scoured the global research peptide and chemical market to offer you our top recommendation for the online purchase of MK-677.

Our go-to choice is:

Peptide Sciences

This US-based vendor easily ships the world’s highest-quality peptides and research chemicals to the UK and around the world. Let’s explore the great features of this leading online source.

  • Product Quality is Guaranteed: All products are synthesized within the USA in alliance with ISO 9001:2008 and WHO/GMP-approved manufacturers. Authenticity and purity levels of 99% and above are verified with certificates of analysis from credible third-party labs. Methods of analysis include mass spectrometry (MS) and high-performance liquid chromatography (HPCL), the industry standards for accuracy and reliability.
  • Competitively Priced: In-house and domestic production practices allow the vendor to offer superior products at low prices. A vial of 60 MK-677 capsules (12.5mg each) costs just $125, and discounts are available on larger buys.
  • International Shipping: Peptide Sciences offers shipping to select destinations worldwide for a low, flat fee. Most deliveries go out within 24 hours of ordering for arrival in 7-10 business days.
  • Buy Online Safely and Easily: The checkout process is smooth and quick on the user-friendly site, and client data is protected with the latest SSL encryption technology. Choose from many acceptable payment methods, including credit cards and crypto.
  • Track Record of Total Customer Satisfaction: Peptide Sciences wins rave reviews for its superior client service. Attentive staff responds to all questions via email in less than 48 hours, and you will not be charged for the replacement of mistaken orders. The website is also full of useful content and knowledgeable articles citing expert sources.

With guaranteed product quality, safety, and affordability, researchers in the UK and around the world prefer Peptide Sciences.

Buy MK-677 from the #1 online Peptides vendor in the world...

MK-677 Benefits

MK-677 has shown several benefits in both human and animal studies, and ongoing clinical trials are promising. Here are the primary findings to date:

GH Deficiency Treatment

MK-677 has been the subject of numerous studies as a potential treatment and diagnostic tool for GH deficiency in both children and adults. Due to its oral bioavailability and low basal therapeutic dose, it is considered a favorable alternative to traditional rhGH injections. Studies on MK-677 in children with idiopathic GH deficiency have shown it to raise levels of endogenous GH and IGF-I. Another study on MK-677 administration in adult males with childhood-onset GH deficiency similarly affected significant increases in serum GH and IGF-1 with short-term treatment [24, 25, 26, 27].

While MK-677 is designated as an orphan drug in this capacity in both the UK and the US, it has also been studied in populations with symptomatically declining GH levels that are not formally diagnosed as GHD. This includes elderly and obese subjects, in whom MK-677 has likewise been shown to elicit enhanced GH and IGF-1 levels to varying therapeutic effects [28, 29, 30].

Bone Health

GH affects optimal bone density and formation, prompting research into the outcome of MK-677 administration on bone health in elderly and osteoporotic subjects.

In one study on MK-677 administration in women exhibiting postmenopausal osteoporosis, MK-677 was shown to positively influence bone resorption, formation, and density. Another clinical trial examining MK-677 in elderly hip fracture patients indicated its potential to aid functional recovery, measured in gait speed and balance. In addition to geriatric applications, a trial on MK-677 use in younger obese males yielded favorable outcomes on bone formation and resorption [31, 32, 33, 34].

Physical Composition

MK-677 has also been analyzed for its effects on body composition, especially in obese subjects in whom GH levels are typically low. One short-term study on MK-677 administration in obese male subjects found that MK-677 not only raised GH and IGF-1 levels, but yielded increased lean muscle mass, reduced adiposity, and a transient rise in basal metabolic rate [35].

Further analysis has shown MK-677 to combat muscular degeneration in subjects with diet-induced catabolism, indicating its potential use in the prevention of wasting due to chronic diseases. It has similarly been shown to raise GH and IGf-1 levels in elderly subjects to potentially combat age-related muscle loss. While the short-term anabolic impacts of MK-677 are notable, more conclusive studies on its long-term use in both healthy and diseased subjects are needed [2, 36].


MK-677 has been shown to profoundly improve sleep in both young and elderly subjects. While many GHRPs have been studied in this capacity, MK-677 has evidenced particular effectiveness in aiding sleep, especially in elderly subjects. In one study, subjects administered single daily doses of MK-677 before bedtime saw increases in stage 4 and REM sleep duration, with decreased REM latency observed in older adults [2, 37, 38].

While these comprise the most notable findings, MK-677 is under review for numerous additional areas of clinical impact. Further potential benefits include the treatment of neurodegenerative and cardiovascular diseases, both of which are linked with age-related GH decline. In particular, MK-677’s effectiveness as a ghrelin agonist is shown to have neuroprotective benefits in animal models of Alzheimer’s disease. Meanwhile, the GH/ IGF-1 axis upon which MK-677 acts is crucial to vascular function. Broad anti-aging benefits are also in evidence for this and other potent GH secretagogues [39, 40, 41].

P.S: Click here to learn more about the benefits of MK-677!

MK-677 Side Effects

While conclusive studies on the long-term effects of MK-677 use in humans are pending, the available data to date suggests a positive safety profile. Adverse effects tend to be mild and transient, such as those found in one study on MK-677 in healthy older adults [42]:

  • Appetite increase
  • Joint pain
  • Edema
  • Increased blood glucose
  • Decreased insulin sensitivity
  • Increased cortisol (slight)

Additional trials on GH-deficient subjects occasionally resulted in [25, 32]:

  • Headache
  • Facial flushing
  • Digestive problems
  • Night sweats
  • Dry skin
  • Abdominal pain
  • Tingling
  • Numbness

Risks of serious complications due to increased blood pressure and metabolic changes are more likely in elderly and diabetic patients. As such, MK-67 is not recommended in pre-diabetic and diabetic subjects, as well as those with heart failure or acute cardiovascular disease. Due to the possible carcinogenicity of elevated GH and IGF-1 levels, specialists advise particular caution regarding GHS administration in subjects with any history of cancer [33, 43].

In general, MK-677 delivered via oral administration is shown to be well-tolerated in studies lasting up to two years. Findings on longer-term effects await further research.

To minimize side effects, researchers are advised to purchase MK-677 from legitimate sources that provide valid quality testing reports. Adverse effects may vary with dosage. It is prudent to begin with a low dose and increase gradually without exceeding the dosages covered in experimental trials. Indefinite use is neither studied nor recommended.
If serious adverse reactions occur, cease use immediately and seek medical attention.

Click here to learn more about the MK-677 dosage recommendations based on published studies to date.

Buy MK-677 UK

MK-677 Dosage

Given its status as an experimental research compound, MK-677 does not currently have standard guidelines. However, clinical studies to date have presented some relevant findings, as follows [24, 25, 27]:

  • MK-677 is suited to oral administration and is best taken on an empty stomach.
  • The half-life of MK-677 is 24 hours.
  • Effects are dose-dependent.
  • The most common daily dose in relevant trials is 25mg daily.
  • Studies have included daily doses ranging from 2mg-50mg. Trial durations range from several days to 2 years.
  • Some trials feature dose cycles with intermittent periods of rest.
  • Cycle durations vary widely. For example, one study on MK-677 administration in adult males with childhood-onset GHD involved 4-day dosage windows with 28-day breaks. Another trial on children with GHD featured 7-day administration periods followed by 7-day rest periods.
  • Most cycling schedules feature 2-8 weeks of administration followed by breaks of 2-4 weeks.

Sample MK-677 Dosing Protocol

With these observations in mind, a sample dosing protocol of MK-677 may look like this.

  • MK-677 Dosage: 25mg per day, ingested orally
  • Course Duration: 2-8 weeks followed by several weeks of abstention
  • Notes: Administration is recommended once daily before sleep and on an empty stomach. A single bottle of 60 12.5mg MK-677 capsules from our preferred vendor would supply a dosage window of 30 days.

Researchers are encouraged to follow these measures and stay up-to-date on emerging studies on MK-677 and other GH secretagogues in therapeutic contexts.

MK-677 in the UK | Overall

MK-677 is a potent growth hormone secretagogue that has captured the interest of clinical researchers due to its range of therapeutic applications, oral bioavailability, and positive safety profile. Though often studied alongside GHS peptides, MK-677 is classed as a peptide mimetic, proven to be more stable and longer-acting than comparable peptidyl compounds.

While MK-677 has yet to receive regulatory approval as a medical product, it is currently under close evaluation in the UK as a designated orphan drug for the treatment of GH deficiency. Additional benefits are widely evidenced in ongoing experimental trials.

UK researchers interested in MK-677 can optimize their studies with a purchase from Peptide Sciences, the world’s leading provider of research peptides and chemicals.

Visit them today to enjoy rapid delivery, low prices, and proven quality!


  1. PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 6450830, Ibutamoren mesylate; [cited 2023 Jan. 20]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Ibutamoren-mesylate
  2. Sigalos, J. T., & Pastuszak, A. W. (2018). The Safety and Efficacy of Growth Hormone Secretagogues. Sexual medicine reviews, 6(1), 45. https://doi.org/10.1016/j.sxmr.2017.02.004
  3. Patchett AA, Nargund RP, Tata JR, Chen MH, Barakat KJ, Johnston DB, Cheng K, Chan WW, Butler B, Hickey G, et al. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7001-5. doi: 10.1073/pnas.92.15.7001. PMID: 7624358; PMCID: PMC41459.
  4. Ema. EU/3/17/1882 [Internet]. European Medicines Agency. 2021 [cited 2023Jan20]. Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3171882#
  5. Freidinger, R. M. (1989). Non-peptide ligands for peptide receptors. Trends in Pharmacological Sciences, 10(7), 270-274. https://doi.org/10.1016/0165-6147(89)90026-6
  6. Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., Pastuszak, A. W., & Lipshultz, L. I. (2020). Beyond the androgen receptor: The role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology, 9(Suppl 2), S149. https://doi.org/10.21037/tau.2019.11.30
  7. Bidlingmaier M, Strasburger CJ. Growth hormone. Handb Exp Pharmacol. 2010;(195):187-200. doi: 10.1007/978-3-540-79088-4_8. PMID: 20020365.
  8. Tian, J., Wang, T., Wang, Q., Guo, L., & Du, H. (2019). MK0677, a Ghrelin Mimetic, Improves Neurogenesis but Fails to Prevent Hippocampal Lesions in a Mouse Model of Alzheimer’s Disease Pathology. Journal of Alzheimer's disease : JAD, 72(2), 467. https://doi.org/10.3233/JAD-190779
  9. Gianfabio Giorgioni, Fabio Del Bello, Wilma Quaglia, Luca Botticelli, Carlo Cifani, E. Micioni Di Bonaventura, M. V. Micioni Di Bonaventura, and Alessandro Piergentili. Advances in the Development of Nonpeptide Small Molecules Targeting Ghrelin Receptor.Journal of Medicinal Chemistry 2022 65 (4), 3098-3118DOI: 10.1021/acs.jmedchem.1c02191.
  10. Participation, E. (1979, January 31). Misuse of drugs act 1971. Legislation.gov.uk. Retrieved March 7, 2022, from https://www.legislation.gov.uk/ukpga/1971/38/contents
  11. Ema. Medicines for human use under evaluation – european agency [Internet]. European Medicines Agency. 2022 [cited 2022Nov28]. Available from: https://www.ema.europa.eu/en/medicines/medicines-human-use-under-evaluation
  12. Notice of opportunity for hearing (Nooh) manookian, Edward 8/5/16 [Internet]. U.S. Food and Drug Administration. FDA; 2016 [cited 2022Sep23]. Available from: https://www.fda.gov/regulatory-information/electronic-reading-room/notice-opportunity-hearing-nooh-manookian-edward-8516
  13. Van Wagoner, R. M., Eichner, A., Bhasin, S., Deuster, P. A., & Eichner, D. (2017). Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. JAMA, 318(20), 2004-2010. https://doi.org/10.1001/jama.2017.17069
  14. The prohibited list. World Anti-Doping Agency. (2022, February 9). Retrieved April 15, 2022, from https://www.wada-ama.org/en/prohibited-list?q=growth
  15. M.J., Evans-Brown & Mcveigh, Jim & C, Perkins & Bellis, Mark. (2012). Human Enhancement Drugs – The Emerging Challenges to Public Health.
  16. Leaney, AE, Beck, P, Biddle, S, et al. Analysis of supplements available to UK consumers purporting to contain selective androgen receptor modulators. Drug Test Anal. 2021; 13: 122– 127. https://doi.org/10.1002/dta.2908
  17. Macdonald G. Ema proposes quality guidelines for synthetic peptides and oligonucleotides [Internet]. Regulatory Affairs Professionals Society (RAPS). [cited 2022Nov28]. Available from: https://www.raps.org/news-and-articles/news-articles/2022/9/ema-proposes-quality-guidelines-for-synthetic-pept
  18. Peptide synthesis market share, size and industry growth analysis 2021 – 2026 [Internet]. IndustryARC. [cited 2022Dec17]. Available from: https://www.industryarc.com/Research/Peptide-Synthesis-Market-Research-505605
  19. The impact of the European pharmacopeia regulations for peptides during the change of manufacturer at late phase [Internet]. Knowledge Centre. 2021 [cited 2022Dec17]. Available from: https://www.almacgroup.com/knowledge/library/the-impact-of-the-european-pharmacopeia-regulations-for-peptides-during-the-change-of-manufacturer-at-late-phase/
  20. Establishment of a guideline on the development and manufacture synthetic peptides – scientific European Medicines Agency [Internet]. European Medicines Agency. 2022 [cited 2022Dec17]. Available from: https://www.ema.europa.eu/en/establishment-guideline-development-manufacture-synthetic-peptides-scientific-guideline#current-version-section
  21. Peptide drug conjugates market size & share report, 2030 [Internet]. Peptide Drug Conjugates Market Size & Share Report, 2030. [cited 2022Dec17]. Available from: https://www.grandviewresearch.com/industry-analysis/peptide-drug-conjugates-market-report
  22. Brennan, R., Wells, J. G., & Van Hout, M. C. (2014). An unhealthy glow? A review of melanotan use and associated clinical outcomes. Performance Enhancement & Health, 3(2), 78–92. doi:10.1016/j.peh.2015.06.001
  23. Callaghan III, D. J. (2018). A glimpse into the underground market of melanotan. Dermatology Online Journal, 24(5). http://dx.doi.org/10.5070/D3245040036 Retrieved from https://escholarship.org/uc/item/2gz9f9jk
  24. Codner E, Cassorla F, Tiulpakov AN, Mericq MV, Avila A, Pescovitz OH, Svensson J, Cerchio K, Krupa D, Gertz BJ, Murphy G. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children. Clin Pharmacol Ther. 2001 Jul;70(1):91-8. doi: 10.1067/mcp.2001.116514. PMID: 11452249.
  25. Ian M. Chapman, Ora H. Pescovitz, Gail Murphy, Theresa Treep, Kristine A. Cerchio, David Krupa, Barry Gertz, William J. Polvino, Emily H. Skiles, Suzan S. Pezzoli, Michael O. Thorner, Oral Administration of Growth Hormone (GH) Releasing Peptide-Mimetic MK-677 Stimulates the GH/Insulin-Like Growth Factor-I Axis in Selected GH-Deficient Adults, The Journal of Clinical Endocrinology & Metabolism, Volume 82, Issue 10, 1 October 1997, Pages 3455–3463, https://doi.org/10.1210/jcem.82.10.4297
  26. Yau, M., & Rapaport, R. (2021). Treatment of Pediatric Growth Hormone Deficiency With Oral Secretagogues Revisited. Journal of the Endocrine Society, 5(7). https://doi.org/10.1210/jendso/bvab096
  27. Ibutamoren Mesylate – University of Maryland, Baltimore [Internet]. [cited 2023Jan20]. Available from: https://archive.hshsl.umaryland.edu/bitstream/handle/10713/14872/Ibutamoren%20mesylate_Final_2021_02.pdf?sequence=1
  28. J. Svensson, L. Lönn, J.-O. Jansson, G. Murphy, D. Wyss, D. Krupa, K. Cerchio, W. Polvino, B. Gertz, I. Boseaus, L. Sjöström, B.-Å. Bengtsson, Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure, The Journal of Clinical Endocrinology & Metabolism, Volume 83, Issue 2, 1 February 1998, Pages 362–369, https://doi.org/10.1210/jcem.83.2.4539
  29. I M Chapman, M A Bach, E Van Cauter, M Farmer, D Krupa, A M Taylor, L M Schilling, K Y Cole, E H Skiles, S S Pezzoli, M L Hartman, J D Veldhuis, G J Gormley, M O Thorner, Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects, The Journal of Clinical Endocrinology & Metabolism, Volume 81, Issue 12, 1 December 1996, Pages 4249–4257, https://doi.org/10.1210/jcem.81.12.8954023
  30. I M Chapman, M L Hartman, S S Pezzoli, M O Thorner, Enhancement of pulsatile growth hormone secretion by continuous infusion of a growth hormone-releasing peptide mimetic, L-692,429, in older adults–a clinical research center study, The Journal of Clinical Endocrinology & Metabolism, Volume 81, Issue 8, 1 August 1996, Pages 2874–2880, https://doi.org/10.1210/jcem.81.8.8768844
  31. Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D, Cerchio K, Gertz BJ. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group. J Bone Miner Res. 1999 Jul;14(7):1182-8. doi: 10.1359/jbmr.1999.14.7.1182. PMID: 10404019.
  32. M. G. Murphy, S. Weiss, M. McClung, T. Schnitzer, K. Cerchio, J. Connor, D. Krupa, B. J. Gertz, Effect of Alendronate and MK-677 (a Growth Hormone Secretagogue), Individually and in Combination, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women, The Journal of Clinical Endocrinology & Metabolism, Volume 86, Issue 3, 1 March 2001, Pages 1116–1125, https://doi.org/10.1210/jcem.86.3.7294
  33. Adunsky A, Chandler J, Heyden N, Lutkiewicz J, Scott BB, Berd Y, Liu N, Papanicolaou DA. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr. 2011 Sep-Oct;53(2):183-9. doi: 10.1016/j.archger.2010.10.004. Epub 2010 Nov 9. PMID: 21067829.
  34. Svensson J, Ohlsson C, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Baylink D, Mohan S, Bengtsson BA. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males. J Bone Miner Res. 1998 Jul;13(7):1158-66. doi: 10.1359/jbmr.1998.13.7.1158. PMID: 9661080.
  35. Svensson J, Lönn L, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus I, Sjöström L, Bengtsson BA. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998 Feb;83(2):362-9. doi: 10.1210/jcem.83.2.4539. PMID: 9467542.
  36. Murphy MG, Plunkett LM, Gertz BJ, He W, Wittreich J, Polvino WM, Clemmons DR. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab. 1998 Feb;83(2):320-5. doi: 10.1210/jcem.83.2.4551. PMID: 9467534.
  37. Copinschi G, Leproult R, Van Onderbergen A, Caufriez A, Cole KY, Schilling LM, Mendel CM, De Lepeleire I, Bolognese JA, Van Cauter E. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology. 1997 Oct;66(4):278-86. doi: 10.1159/000127249. PMID: 9349662.
  38. Ghigo E. Growth hormone secretagogues: Basic findings and clinical implications. Amsterdam etc.: Elsevier; 2008.
  39. Jeong Y-o, Shin SJ, Park JY, Ku BK, Song JS, Kim J-J, Jeon SG, Lee SM, Moon M. MK-0677, a Ghrelin Agonist, Alleviates Amyloid Beta-Related Pathology in 5XFAD Mice, an Animal Model of Alzheimer’s Disease. International Journal of Molecular Sciences. 2018; 19(6):1800. https://doi.org/10.3390/ijms19061800
  40. Thum T, Hoeber S, Froese S, Klink I, Stichtenoth DO, Galuppo P, Jakob M, Tsikas D, Anker SD, Poole-Wilson PA, Borlak J, Ertl G, Bauersachs J. Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circ Res. 2007 Feb 16;100(3):434-43. doi: 10.1161/01.RES.0000257912.78915.af. Epub 2007 Jan 18. PMID: 17234973.
  41. Milanesi A, Weinreb JE. Diabetes in the Elderly. [Updated 2020 Sep 25]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
  42. Nass, R., Pezzoli, S. S., Oliveri, M. C., Patrie, J. T., Clasey, J. L., Heymsfield, S. B., Bach, M. A., Vance, M. L., & Thorner, M. O. (2008). Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults: A Randomized, Controlled Trial. Annals of internal medicine, 149(9), 601. https://doi.org/10.7326/0003-4819-149-9-200811040-00003
  43. Weroha, S. J., & Haluska, P. (2012). IGF System in Cancer. Endocrinology and metabolism clinics of North America, 41(2), 335. https://doi.org/10.1016/j.ecl.2012.04.014

Table of Contents
    Add a header to begin generating the table of contents